NVOHNovo Nordisk A/S (B Shares) ADRhedged

Grow my money1y track recordRanked #1,899 of 2,960 in this goal

Seeks to provide investment results that correspond generally to the total return of the ordinary shares of Novo Nordisk A/S (B Shares).

By ADRH · Launched 2025

Annual Cost

0.19%

#957 of 5,562 · low cost

Fund Size

$5M

#5,119 of 5,562 · small

Return (1Y)Goal

-39.0%

Track Record

1 year

#4,078 of 5,562 · young

Performance

Total-return NAV · USD

Growth of $10,000

$6,274-37.3%

Total-return NAV, USD. Net of fund fees, before tax.

Classification

How Beacon categorizes this fund

Asset class

Equity

Region

Europe

What it actually holds

By weight

Concentration

Top 3 holdings = 99.8% of fundconcentrated

Novo Nordisk A/S

98.6%

DREYFUS TRSRY SECURITIES

1.2%

CANADIAN IMPERIAL BANK OF COMMERCE

0.1%

Asset allocation

Stocks

96.0%

Cash

4.0%

By sector

Healthcare

100.0%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years

Volatility (1Y)

49.2%High

Year-on-year price swings

Max drawdown

-61.6%Severe

Worst peak-to-trough loss

Sharpe (3Y)

Unavailable

Needs 3+ years of history

Sortino (3Y)

Not yet

Needs 3+ years of history

Where to buy

Listing

Exchange: NYSE Arca

Full fund details

Objective: Seeks to provide investment results that correspond generally to the total return of the ordinary shares of Novo Nordisk A/S (B Shares).
Strategy: Invests primarily in ADRs of Novo Nordisk A/S (B Shares) and uses a currency swap to hedge against fluctuations between the U.S. dollar and the Danish krone. Maintains cash or cash equivalents for liquidity. The Series does not seek to replicate a specified index.
Inception date: January 6, 2025
Fund family: ADRH